AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03512366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Desarda's technique
Description: It will be performed by separating a strip from the upper leaf of the external oblique aponeurosis in continuity with the muscle and suturing it with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence.
Study NCT03512366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein's technique
Description: A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring.
Study NCT04624412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Moderate Intensity Exercise
Description: Continuous Aerobic Moderate Intensity Exercise~* 5-10 min warm up~* 30 min moderate aerobic exercise (Treadmill walking exercise)~* Constant intensity at 50% - 70% of max HR (3-6 METS)~* 5-10 min cool down
Study NCT01734317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Transfer Ag
Description: A soft silicone wound contact layer.
Study NCT01658657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Study NCT01658657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Study NCT01658657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study NCT01658657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Study NCT01658657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Study NCT04624412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic (Mild intensity Exercise)
Description: Continuous Aerobic (Mild intensity Exercise)~* 5-10 min warm up~* 30 min mild aerobic exercise (Treadmill walking exercise)~* Constant intensity at 30-50 % of max HR (1-3 METS)~* 5-10 min cool down
Study NCT04559347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine (EXPAREL®)/Bupivacaine
Description: Single shot for erector spinae block
Study NCT01658657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Study NCT01658657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril/hydrochlorothiazide
Description: This is a combination pill
Study NCT01715584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sevoflurane/oxygen/air/nitrous oxide
Description: Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
Study NCT03378063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transplantation of mesenchymal stem cell
Description: allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
Study NCT03378063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no transplantation of mesenchymal stem cell
Description: MSC transplantation will be not given to preterm infants
Study NCT03752645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transverse Many Channels Laser Instrument
Description: The device consists of a control box and 4 sets of two light-emitting nasal probes. Prior to treatment, each patient put on a pair of black tinted glasses, and had the nasal probes gently placed into both nostrils. A turn-on switch on the control box activated the probe and the timer was set at 15 minutes during which time 36 J of light energy was delivered to each nostril.
Study NCT01817816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox_A
Study NCT03692819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Oral Drops
Description: Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
Study NCT03453788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LETSGO app
Description: LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
Study NCT04559347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine (0.5% bolus followed by 0.2% infusion)
Description: Continuous catheter infusion for erector spinae plane block
Study NCT02263092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
Study NCT02428478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine
Description: 200 mg administered 2 hours before normal sleep time
Study NCT02428478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo-matching desipramine administered 2 hours before normal sleep time
Study NCT01817816 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Botox_A
Study NCT01817816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox_B
Study NCT01817816 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Botox_B
Study NCT01515033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise training
Description: The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
Study NCT00375102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT00375102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response
Study NCT02528240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMS
Study NCT02528240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Study NCT02528240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: + occlusive membrane
Study NCT02528240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conebeam CT
Study NCT02528240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conebeam CT
Study NCT00706017 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00384787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA009-00-VP
Description: HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
Study NCT00384787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
Study NCT02504229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells co-cultured with cytokine-induced killer cells
Study NCT02504229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gimeracil and Oteracil Porassium Capsules
Study NCT02504229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimeracil and Oteracil Porassium Capsules
Study NCT02504229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT02504229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01501058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-assisted social skills training program for adolescents with autism spectrum disorder
Description: The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
Study NCT01501058 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed intervention
Description: Intervention is provided to Waitlist Control Group after waiting for 14 weeks
Study NCT02263092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be applied by a DC stimulator (NeuroConn, Germany) using a pair of saline-soaked sponge electrodes (surface 35 and 36cm²). tDCS will be applied to Cz and Oz according to International 10-20 EEG system. In the anodal tDCS, the anode will be placed in Cz and cathode in Oz. In the cathodal tDCS the inverse position will be done. Parameters of current intensity and duration (dose) used were 2 mA stimulation intensity for 20 minutes with current ramping up and down of 10 seconds each.For sham, the same position of anodal tDCS will be assumed, however, current duration is only 30 seconds, with current ramping up and down of 10 seconds each. Moreover, the electrostimulation device is automatically turned off without patient's perception. Thus, patients experience early sensations (mild to moderate tingling) in stimulation site without inducing effect. Moreover, after each tDCS session, patients will answer adverse effects questionnaire.
Study NCT02263092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest
Description: 15 or 30 minutes seat without move the legs
Study NCT03794635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly 45 minute Sessions
Description: The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:~1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish)~2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window.~Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention.
Study NCT01820923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: 2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
Study NCT01820923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
Study NCT01820923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (SHAM)
Description: The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
Study NCT01820923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (SHAM)
Description: The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
Study NCT02137993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-prexa
Description: A-prexa 5-20 mg for 6 weeks
Study NCT02137993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyprexa
Description: Zyprexa 5-20 mg for 6 weeks
Study NCT02019056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo /bid P.O
Study NCT02019056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-1
Study NCT02019056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-2 : MG1000mg, Placebo /bid P.O
Study NCT02019056 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: metadoxine
Study NCT01511939 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pennsaid
Description: Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
Study NCT03533283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
Study NCT03533283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
Study NCT03533283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
Study NCT03533283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
Study NCT03533283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
Study NCT03533283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Df-IAB22M2C
Description: Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
Study NCT03524118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single ascending doses of clesrovimab will be administered via IM injection.
Study NCT03524118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.
Study NCT00208026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% Cream
Description: Open label single arm
Study NCT01115322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Foam without irradiation
Description: Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period.~This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study NCT01115322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Foam with UVA and UVB irradiation
Description: Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study NCT01115322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Foam with UVA, UVB, and visible light
Description: Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study NCT01115322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam without irradiation
Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study NCT01115322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam with UVA and UVB irradiation
Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study NCT01115322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam with UVA and UVB and visible light irradiation
Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study NCT01115322 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No Treatment without irradiation
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study NCT01115322 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No Treatment with UVA and UVB irradiation
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study NCT02159300 — intervention group
Intervention type: BEHAVIORAL
Intervention: experience brain activity recording
Description: Intervention: experience brain activity recording
Study NCT00874211 — intervention group
Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: By dental and medical assessments.
Study NCT02800187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
Study NCT02800187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
Study NCT01951001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.